AI English summary of an SEC filing — figures as filed
Biogen BIIBBiogen reported first quarter Q1 2025 total revenue of $2,431 million, an increase of 6% year-over-year, GAAP diluted EPS of $1.64, and Non-GAAP diluted EPS of $3.02. Product revenue increased 3% at constant currency and 1% at actual currency year-over-year in the same period.
Key points
AI summaryBiogen reported first quarter Q1 2025 total revenue of $2,431 million, an increase of 6% year-over-year, GAAP diluted EPS of $1.64, and Non-GAAP diluted EPS of $3.02. Product revenue increased 3% at constant currency and 1% at actual currency year-over-year in the same period.
The company said an upfront transaction payment of $165 million to Stoke Therapeutics related to the collaboration and license agreement for zorevunersen had an impact of approximately ($0.95) on GAAP and Non-GAAP diluted EPS. This upfront payment is included in acquired in-process research and development, upfront and milestone expense of approximately $201 million for Q1 2025.
Biogen said rare disease revenue for Q1 2025 was $563 million, an increase of 33% year-over-year, while multiple sclerosis product revenue was $953 million, a decrease of 11%. The company's Chief Executive Officer explained that approximately 45% of total product revenue in Q1 was derived from medicines outside the MS business.
The company updated its full-year Non-GAAP diluted EPS guidance from prior guidance of $15.25 to $16.25 to $14.50 to $15.50. It said the update reflects the impact of approximately ($0.95) from the Stoke upfront payment and a benefit of +$0.20 mainly from foreign exchange, and expects full-year total revenue to decline by a mid-single digit percentage at constant currency.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
First Quarter Q1 2025 Total Revenue and EPS
Biogen reported first quarter Q1 2025 total revenue of $2,431 million, an increase of 6% year-over-year, GAAP diluted EPS of $1.64, and Non-GAAP diluted EPS of $3.02. Product revenue increased 3% at constant currency and 1% at actual currency year-over-year in the same period.
Source · Based on the filing body and exhibits
Stoke Therapeutics $165 million Upfront Payment
The company said an upfront transaction payment of $165 million to Stoke Therapeutics related to the collaboration and license agreement for zorevunersen had an impact of approximately ($0.95) on GAAP and Non-GAAP diluted EPS. This upfront payment is included in acquired in-process research and development, upfront and milestone expense of approximately $201 million for Q1 2025.
Source · Based on the filing body and exhibits
Rare Disease and MS Product Revenue
Biogen said rare disease revenue for Q1 2025 was $563 million, an increase of 33% year-over-year, while multiple sclerosis product revenue was $953 million, a decrease of 11%. The company's Chief Executive Officer explained that approximately 45% of total product revenue in Q1 was derived from medicines outside the MS business.
Source · Based on the filing body and exhibits
Full-Year 2025 Non-GAAP EPS Guidance Update
The company updated its full-year Non-GAAP diluted EPS guidance from prior guidance of $15.25 to $16.25 to $14.50 to $15.50. It said the update reflects the impact of approximately ($0.95) from the Stoke upfront payment and a benefit of +$0.20 mainly from foreign exchange, and expects full-year total revenue to decline by a mid-single digit percentage at constant currency.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…